IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system
Shoji Sanada, Daihiko Hakuno, Luke J Higgins, Eric R Schreiter, Andrew N J McKenzie, Richard T Lee, Shoji Sanada, Daihiko Hakuno, Luke J Higgins, Eric R Schreiter, Andrew N J McKenzie, Richard T Lee
Abstract
ST2 is an IL-1 receptor family member with transmembrane (ST2L) and soluble (sST2) isoforms. sST2 is a mechanically induced cardiomyocyte protein, and serum sST2 levels predict outcome in patients with acute myocardial infarction or chronic heart failure. Recently, IL-33 was identified as a functional ligand of ST2L, allowing exploration of the role of ST2 in myocardium. We found that IL-33 was a biomechanically induced protein predominantly synthesized by cardiac fibroblasts. IL-33 markedly antagonized angiotensin II- and phenylephrine-induced cardiomyocyte hypertrophy. Although IL-33 activated NF-kappaB, it inhibited angiotensin II- and phenylephrine-induced phosphorylation of inhibitor of NF-kappa B alpha (I kappa B alpha) and NF-kappaB nuclear binding activity. sST2 blocked antihypertrophic effects of IL-33, indicating that sST2 functions in myocardium as a soluble decoy receptor. Following pressure overload by transverse aortic constriction (TAC), ST2(-/-) mice had more left ventricular hypertrophy, more chamber dilation, reduced fractional shortening, more fibrosis, and impaired survival compared with WT littermates. Furthermore, recombinant IL-33 treatment reduced hypertrophy and fibrosis and improved survival after TAC in WT mice, but not in ST2(-/-) littermates. Thus, IL-33/ST2 signaling is a mechanically activated, cardioprotective fibroblast-cardiomyocyte paracrine system, which we believe to be novel. IL-33 may have therapeutic potential for beneficially regulating the myocardial response to overload.
Figures
References
- Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Annu. Rev. Physiol. 1997;59:551–571.
- McKinsey T.A., Olson E.N. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J. Clin. Invest. . 2005;115:538–546. doi: 10.1172/JCI200524144.
- Diez J., Gonzalez A., Lopez B., Querejeta R. Mechanisms of disease: pathologic structural remodeling is more than adaptive hypertrophy in hypertensive heart disease. Nat. Clin. Pract. Cardiovasc. Med. 2005;2:209–216.
- Baudino T., Carver W., Giles W.R., Borg T.K. Cardiac fibroblasts: friend or foe? Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1015–H1026.
- Grossman W., Jones D., McLaurin L.P. Wall stress and patterns of hypertrophy in the human left ventricle. J. Clin. Invest. 1975;56:56–64.
- Weinberg E.O., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961–2966.
- Iwahana H., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur. J. Biochem. 1999;264:397–406.
- Weinberg E.O., et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721–726.
- Shimpo M., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186–2190.
- Kumar S., Minnich M.D., Young P.R. ST2/T1 protein functionally binds to two secreted proteins from Balb/c 3T3 and human umbilical vein endothelial cells but does not bind interleukin 1. J. Biol. Chem. 1995;270:27905–27913.
- Gayle M.A., et al. Cloning of a putative ligand for the T1/ST2 receptor. J. Biol. Chem. 1996;271:5784–5789.
- Schmitz J., et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479–490.
- Manabe I., Shindo T., Nagai R. Gene expression in fibroblasts and fibrosis: involvement in cardiac hypertrophy. Circ. Res. 2002;91:1103–1113.
- Marian A.J. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet. 2000;355:58–60.
- Goldsmith E.C., et al. Organization of fibroblasts in the heart. Dev. Dyn. 2004;230:787–794.
- Kawano S., et al. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc. Res. 2005;67:689–698.
- Hirotani S., et al. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 2002;105:509–515.
- Townsend M.J., Fallon P.G., Matthews D.J., Jolin H.E., McKenzie A.N. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J. Exp. Med. 2000;191:1069–1076.
- Kuster G.M., et al. Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload. Circulation. . 2005;111:420–427.
- Shioi T., et al. Increased expression of interleukin-1 beta and monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 in the hypertrophied and failing heart with pressure overload. Circ. Res. 1997;81:664–671.
- Okada K., et al. Prolonged endoplasmic reticulum stress in hypertrophic and failing heart after aortic constriction: possible contribution of endoplasmic reticulum stress to cardiac myocyte apoptosis. Circulation. 2004;110:705–712.
- Yang G., et al. Cyclosporine reduces left ventricular mass with chronic aortic banding in mice, which could be due to apoptosis and fibrosis. J. Mol. Cell. Cardiol. 2001;33:1505–1514.
- Dunne A., O’Neill L.A. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE. 2003;2003:re3.
- Matsuzawa A., et al. ROS-dependent activation of the TRAF6-ASK1-p38 pathway is selectively required for TLR4-mediated innate immunity. Nat. Immunol. 2005;6:587–592.
- Ninomiya-Tsuji J., et al. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature. 1999;398:252–256.
- Zhang D., et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. . 2000;6:556–563.
- Purcell N.H., et al. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 2001;98:6668–6673.
- Freund C., et al. Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo. Circulation. 2005;111:2319–2325.
- Ha T., et al. Reduced cardiac hypertrophy in toll-like receptor 4-deficient mice following pressure overload. Cardiovasc. Res. . 2005;68:224–234.
- Hoffmann A., Baltimore D. Circuitry of nuclear factor kappaB signaling. Immunol. Rev. 2006;210:171–186.
- Nelson D.E., et al. Oscillations in NF-kappaB signaling control the dynamics of gene expression. Science. 2004;306:704–708.
- Rockman H.A., Wachhorst S.P., Mao L., Ross J.J. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am. J. Physiol. . 1994;266:H2468–H2475.
- Rapacciuolo A., et al. Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J. Am. Coll. Cardiol. 2001;38:876–882.
- Ha T., et al. Blockade of MyD88 attenuates cardiac hypertrophy and decreases cardiac myocyte apoptosis in pressure overload-induced cardiac hypertrophy in vivo. Am. J. Physiol. Heart Circ. Physiol. 2006;290:H985–H994.
- Hingtgen S.D., et al. Nox2-containing NADPH oxidase and Akt activation play a key role in angiotensin II-induced cardiomyocyte hypertrophy. Physiol. Genomics. 2006;26:180–191.
- Nishida M., et al. G alpha 12/13- and reactive oxygen species-dependent activation of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase by angiotensin receptor stimulation in rat neonatal cardiomyocytes. J. Biol. Chem. . 2005;280:18434–18441.
- Li Q., et al. Nox2 and Rac1 regulate H2O2-dependent recruitment of TRAF6 to endosomal interleukin-1 receptor complexes. Mol. Cell. Biol. 2006;26:140–154.
- Sarkar S., Vellaichamy E., Young D., Sen S. Influence of cytokines and growth factors in ANG II-mediated collagen upregulation by fibroblasts in rats: role of myocytes. Am. J. Physiol. Heart Circ. Physiol. . 2004;287:H107–H117.
- Saccani S., Polentarutti N., Penton-Rol G., Sims J.E., Mantovani A. Divergent effects of LPS on expression of IL-1 receptor family members in mononuclear phagocytes in vitro and in vivo. Cytokine. 1998;10:773–780.
- May L.T., Ndubuisi M.I., Patel K., Garcia D. Interleukin-6 chaperones in blood. Ann. N. Y. Acad. Sci. 1995;762:120–128.
- Economides A.N., et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat. Med. 2003;9:47–52.
- Hsieh P.C., Davis M.E., Gannon J., MacGillivray C., Lee R.T. Controlled delivery of PDGF-BB for myocardial protection using injectable self-assembling peptide nanofibers. J. Clin. Invest. 2006;116:237–248. doi: 10.1172/JCI25878.
- Yokoyama T., et al. 1999Angiotensin II and mechanical stretch induce production of tumor necrosis factor in cardiac fibroblasts . Am. J. Physiol. 276H1968–H1976.
- Yamamoto K., et al. Induction of tenascin-C in cardiac myocytes by mechanical deformation. Role of reactive oxygen species. J. Biol. Chem. 1999;274:21840–21846.
- Hakuno D., Takahashi T., Lammerding J., Lee R.T. Focal adhesion kinase signaling regulates cardiogenesis of embryonic stem cells. J. Biol. Chem. 2005;280:39534–39544.
- Yamamoto K., Ohki R., Lee R.T., Ikeda U., Shimada K. Peroxisome proliferator-activated receptor gamma activators inhibit cardiac hypertrophy in cardiac myocytes. Circulation. 2001;104:1670–1675.
- Frantz S., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J. Clin. Invest. 1999;104:271–280.
- Schulze P.C., et al. Hyperglycemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J. Biol. Chem. 2004;279:30369–30374.
- Rockman H.A., et al. Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 1991;88:8277–8281.
- Tanaka N., et al. Transthoracic echocardiography in models of cardiac disease in the mouse. Circulation. 1996;94:1109–1117.
- Collins K.A., et al. Accuracy of echocardiographic estimates of left ventricular mass in mice. Am. J. Physiol. Heart Circ. Physiol. . 2001;280:H1954–H1962.
- Takemoto M., et al. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J. Clin. Invest. 1997;99:278–287.
Source: PubMed